SGLT（Sodium-glucose cotransporter）2 阻害薬内服中に 急性腎盂腎炎に伴う真菌性眼内炎を生じた１例: － SGLT2 阻害薬関連の尿路・性器感染症に対する当院での対応を含めて－.

SGLT (sodium-glucose cotransporter) 2 inhibitors enhance urinary glucose excretion by inhibiting glucose reabsorption in the proximal renal tubule. In Japan, it has been administered for diabetes since 2014. Recently, the indication has been expanded to include chronic heart failure and chronic renal failure, and the number of prescriptions will be expected to increase in the future. Although urinary tract and genital tract infections are listed as adverse events of SGLT2 inhibitors, the discontinuation criteria of the drug and optimal follow-up methods are not still clear. Consequently, these are unmet needs within this field. We herein report a case of fungal infection which occurred while the patient was taking a SGLT2 inhibitor. A 77-year-old male with type 2 diabetes mellitus was admitted to our hospital in August 20XX complaining of fever and immobility. On the basis of further examination, he was diagnosed with acute pyelonephritis and underwent antibacterial therapy. Ipragliflozin, an SGLT2 inhibitor, was changed to insulin on admission day. Since Candida glabrata was detected in urine and blood cultures on the fifth day, antifungal therapy was added as antibacterial management. He was introduced to the ophthalmology department due to fungemia, and was diagnosed with fungal endophthalmitis. Due to an improvement of intraocular findings, the patient was discharged on the 42nd day after admission. Because urinary tract infections and genital infections such as necrotizing fasciitis (Fournier's gangrene) have been reported to be associated with SGLT2 inhibitors, urologists need to keep in mind the urological risks of SGLT2 inhibitors. [ABSTRACT FROM AUTHOR]